Combined treatment with CTLA-4 (ipilimumab) and PD-1 (nivolumab) inhibition or BRAF/MEKi, if the tumor shows the specific mutation, are among the only useful options for patients who recur on adjuvant therapy [41,42,43,44]. Here, BRAF is linked to neoplasm.